• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 10
  3. Author

Online ISSN: 2515-8260

Volume7, Issue10

To Determine the Clinical Association between Glaucoma and Systemic Hypertension, as well as the Impact on Visual Morbidity

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 10, Pages 4507-4513

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Aim: To evaluate the clinical correlation of glaucoma with systemic hypertension and its effect on visual morbidity.
Methods: This was a prospective study conducted in the Department of Ophthalmology, Darbhanga Medical College and Hospital, Laheriasarai, Darbhanga, Bihar, India, for  15 months. It was carried out on 110 patients ranging in age from 30 to 70 years old, including recently diagnosed hypertensives as well as previously diagnosed hypertensives that were now undergoing medication and being followed up on. According to new American Heart Association guidelines, hypertensive patients had blood pressure readings of >120/80 mm Hg on two different occasions. Calcium channel blockers (CCB), diuretics, angiotensin transforming enzyme inhibitors (ACE), angiotensin receptor blockers, and beta blockers were the five types of oral hypotensive drug used among the patients. Results: Among the 110 hypertension patients involved in the study, 66 patients (60%) were female and 44 patients (40%) were male. Age group affected was 15.45% between 30-40 years, 31.82% between 40 to 50 years and 52.73% above 50 years, the mean age being 57.7 years. Hypertensive patients diagnosed with having glaucoma had a mean duration of 4.87 years. Among the 45 newly diagnosed patients 30 patients had glaucoma and 15 patients did not have glaucoma. They had been on oral hypertension medications for a duration ranging from 1 month to 6 months. The oral hypotensive medication taken by patients were categorized into 5 groups as calcium channel blockers(CCB), diuretics, angiotensin converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (ARB) and beta blockers.
Conclusion: Hypertension can cause both reduction and elevation in IOP. Treatment of hypertension does lower the IOP and prevent further progression of glaucoma and prevent any visual loss.
Keywords:
  • PDF (147 K)
  • XML
(2021). To Determine the Clinical Association between Glaucoma and Systemic Hypertension, as well as the Impact on Visual Morbidity. European Journal of Molecular & Clinical Medicine, 7(10), 4507-4513.
. "To Determine the Clinical Association between Glaucoma and Systemic Hypertension, as well as the Impact on Visual Morbidity". European Journal of Molecular & Clinical Medicine, 7, 10, 2021, 4507-4513.
(2021). 'To Determine the Clinical Association between Glaucoma and Systemic Hypertension, as well as the Impact on Visual Morbidity', European Journal of Molecular & Clinical Medicine, 7(10), pp. 4507-4513.
To Determine the Clinical Association between Glaucoma and Systemic Hypertension, as well as the Impact on Visual Morbidity. European Journal of Molecular & Clinical Medicine, 2021; 7(10): 4507-4513.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 70
  • PDF Download: 135
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus